Inhibition of methyltransferase reduces the turnover of acetylcholine receptors
- PMID: 3375253
- PMCID: PMC280355
- DOI: 10.1073/pnas.85.11.4032
Inhibition of methyltransferase reduces the turnover of acetylcholine receptors
Abstract
Because of the putative rule of phospholipid methyltransferase reactions in many important membrane and receptor translocation processes, we studied the effect of methyltransferase inhibitors on acetylcholine receptor (AcChoR) turnover in cultured rat skeletal muscle. Inhibition of methyltransferase significantly reduced the normal rate of degradation of AcChoRs, a process that involves endocytosis. Further, under conditions that greatly accelerate the rate of degradation of AcChoRs--i.e., by addition of anti-AcChoR antibody--methyltransferase inhibitors again significantly reduced receptor turnover. AcChoR synthesis was unaffected. Thus, the net effect of this treatment was slowing of the antibody-induced loss of surface AcChoRs. That this drug effect was mediated specifically by inhibition of methylation reactions was suggested by certain additional pharmacologic features: partial reversibility of the effect by methionine, enhancement by homocysteine, and correspondence with marked inhibition of phospholipid methylation. The substrate specificity of the methyltransferase inhibitors capable of reducing AcChoR degradation suggests that phospholipid methylation reactions may be most relevant. Methyltransferase inhibitor drugs may provide a therapeutic strategy in receptor disorders such as myasthenia gravis, in which accelerated receptor endocytosis plays a major role.
Similar articles
-
3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.J Pharmacol Exp Ther. 1993 Nov;267(2):582-9. J Pharmacol Exp Ther. 1993. PMID: 8246131
-
Irreversible inhibition of phospholipid methylation and protein carboxymethylation does not alter acetylcholine receptor function in muscle cells.Exp Neurol. 1984 Nov;86(2):198-207. doi: 10.1016/0014-4886(84)90181-x. Exp Neurol. 1984. PMID: 6489494
-
Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies.Proc Natl Acad Sci U S A. 1985 Dec;82(24):8805-9. doi: 10.1073/pnas.82.24.8805. Proc Natl Acad Sci U S A. 1985. PMID: 3878521 Free PMC article.
-
[Effector-receptors relationship: acetylcholine and myasthenia gravis].Nihon Rinsho. 1979;37(8):3125-30. Nihon Rinsho. 1979. PMID: 390184 Review. Japanese. No abstract available.
-
Autoimmune diseases involving nicotinic receptors.J Neurobiol. 2002 Dec;53(4):656-65. doi: 10.1002/neu.10106. J Neurobiol. 2002. PMID: 12436428 Review.
Cited by
-
Phosphoglyceride biosynthesis in bovine adrenal chromaffin cells.Neurochem Res. 1991 Apr;16(4):505-11. doi: 10.1007/BF00965573. Neurochem Res. 1991. PMID: 1656294
-
DNA methylome perturbations: an epigenetic basis for the emergingly heritable neurodevelopmental abnormalities associated with maternal smoking and maternal nicotine exposure†.Biol Reprod. 2021 Sep 14;105(3):644-666. doi: 10.1093/biolre/ioab138. Biol Reprod. 2021. PMID: 34270696 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources